Parameter
| Biomarker | YKL-40 | Full name | Chitinase 3-Like Protein 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Pathological Confirmation, Prognosis |
| Disease | Frontotemporal Dementia | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | CSF/Plasma (ELISA, Luminex) | ||
| Pathobiological Mechanisms | Secreted by activated microglia, involved in extracellular matrix remodeling, aggravating neuroinflammation. | ||||
| Clinical Availability Status | Research stage | ||||
| Notes and Dynamics | CSF YKL-40 in bvFTD patients is 40% higher than in svPPA, positively correlated with behavioral abnormality scores, an efficacy indicator for NLRP3 inhibitors. | ||||